Researchers develop nanovesicles from activated neutrophils to treat drug-resistant infectious wounds, particularly in diabetic patients.

Researchers at the Research Center for Neutrophil Engineering Technology have developed nanovesicles (NVs) from activated neutrophils, showing promise in treating infectious wounds. The NVs accelerate healing and target deep tissue pathogens, addressing the challenges of drug-resistant infections, particularly in diabetic patients. This innovation may revolutionize complex infectious wound management and boost overall treatment efficacy.